Early GO decision reached ahead of Q2'26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A Key objectives achieved: ...

Early GO decision reached in CAPTIVATE ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A ...

Early GO decision reached ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants ...

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, will present data ...

Creative Biolabs expands its research capabilities, offering diversified tools and services to support global biomedical innovation. SHIRLEY, NY, UNITED STATES, February 27, 2026 /EINPresswire.com/ — ...

— Initial Orders Received and Fulfilled from Multiple Transplant Centers, with YARTEMLEA Now Administered to Both Adult and Pediatric Patients with TA-TMA — SEATTLE--(BUSINESS WIRE)--Omeros ...

Omeros Corporation (NASDAQ: OMER) today announced that the first commercial shipments of YARTEMLEA ® (narsoplimab-wuug) to its distributors were completed last week, with orders from transplant ...

Narsoplimab is a human monoclonal antibody that specifically targets mannan-binding lectin-associated serine protease-2. The Food and Drug Administration has approved Yartemlea ® (narsoplimab-wuug) ...

What Is Yartemlea, and Why Does It Matter? Yartemlea (narsoplimab-wuug) is a new medicine approved by the FDA for treating a rare and serious condition called transplant-associated thrombotic ...

Omeros Corporation (NASDAQ: OMER) today announced a revised date for its conference call to discuss the recent FDA approval of YARTEMLEA® (narsoplimab-wuug), the first and only therapy indicated for ...

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA ® (narsoplimab-wuug) for the treatment of hematopoietic ...